Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes

Next Previous
Trial Profile

Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofogliflozin (Primary) ; Alpha-glucosidase inhibitors; Biguanides; Dipeptidyl peptidase 4 inhibitors; Sulfonylureas; Thiazolidines
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Chugai Pharmaceutical; Sanofi

Most Recent Events

  • 29 Jun 2021 Results (n=774) assessing predictors of Hb after short- and long-term therapy with tofogliflozin (TOFO), a SGLT2i, and explored its impact on Hb in relation to anemia and polycythemia in type 2 diabetes mellitus (T2DM) presented at the 81st Annual Scientific Sessions of the American Diabetes Association
  • 16 Jun 2020 Results of pooled analysis assessing the impact of SGLT2is on plasma volume and beta-hydroxybutyrate according to cardiac workload, presented at the 80th Annual Scientific Sessions of the American Diabetes Association
  • 26 Sep 2013 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top